But the euphoria was short-lived. On May 10, 2024, MacroGenics disclosed that five patients in the study had died. This revelation caused the company's share price to plummet by $11.36, or about 77%, on the same day, prompting numerous analyst downgrades. "We're investigating whether MacroGenics may have downplayed safety concerns associated with vobra duo to inflate its stock price," said Reed Kathrein, the Hagens Berman partner leading the investigation.